eli lilly & co (LLY:EN Paris)
Transactions by ELI LILLY & CO (LLY) in the last 6 months
Virbac SA (ENXTPA:VIRP) entered into an agreement to acquire United States Veterinary products from Eli Lilly and Company (NYSE:LLY) on October 27, 2014. Under the terms of this agreement, Virbac would acquire a combination of titles and rights for the United States on trademarks, marketing authorizations, patents, know-how, customer lists and other assets, related to two major parasiticides, Sentinel®Flavor Tabs and Sentinel® Spectrum. The transaction is subject to ...
Accelerator IV held its first close at $51.1 million on July 29, 2014. Investors in the fund include Eli Lilly, Harris & Harris Group, Johnson & Johnson Development Corporation, The Partnership Fund for New York City, WRF Capital, Pfizer Venture Investments, Alexandria Venture Investments, and Arch Venture Partners.
Arch Venture Partners, L.P.
Eli Lilly and Company
Harris & Harris Group, Inc.
Johnson & Johnson Development Corporation
New York City Investment Fund Manager, Inc.
Pfizer Venture Investments
Alkira Therapeutics, Inc. acquired Sollpura from Eli Lilly and Company (NYSE:LLY) on July 11, 2014. It is intended that Alkira will make all future contingent milestone payments under the license agreement upon product approval and on certain annual sales achievements and will make royalty payments on any product sales after achieving certain sales thresholds of cumulative net sales of Sollpura.
|Abbott Laboratories||$45.50 USD||-0.3455|
|AbbVie Inc||$66.99 USD||+0.0125|
|AstraZeneca PLC||4,539 GBp||-17.00|
|Novo Nordisk A/S||kr264.50 DKK||+3.70|
|Teva Pharmaceutical Industries Ltd||$57.29 USD||+0.11|
|View Industry Companies|